Sandoz Group AG - Asset Resilience Ratio
Sandoz Group AG (SDZ) has an Asset Resilience Ratio of 7.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check SDZ capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Sandoz Group AG's Asset Resilience Ratio has changed over time. See SDZ net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sandoz Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sandoz Group AG (SDZ) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF1.74 Billion | 7.89% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF1.74 Billion | 7.89% |
Asset Resilience Insights
- Limited Liquidity: Sandoz Group AG maintains only 7.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Sandoz Group AG Industry Peers by Asset Resilience Ratio
Compare Sandoz Group AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 6.06% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 3.28% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
China Animal Husbandry Industry Co Ltd
SHG:600195 |
Drug Manufacturers - Specialty & Generic | 3.81% |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915 |
Drug Manufacturers - Specialty & Generic | 25.22% |
Annual Asset Resilience Ratio for Sandoz Group AG (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Sandoz Group AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.89% | CHF1.74 Billion ≈ $2.20 Billion |
CHF22.03 Billion ≈ $27.85 Billion |
+1.91pp |
| 2024-12-31 | 5.98% | CHF1.19 Billion ≈ $1.51 Billion |
CHF19.91 Billion ≈ $25.17 Billion |
+1.18pp |
| 2023-12-31 | 4.80% | CHF933.39 Million ≈ $1.18 Billion |
CHF19.43 Billion ≈ $24.56 Billion |
-- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more